icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
ZcpNanHBYhvT8KVM
Listen
